Papers in Cancer Drug Resistance
Page 9 · newest first
- Overcome cancer drug resistance by targeting epigenetic modifications of centrosomeCancer Drug Resistance · 2019
- Molecular mechanisms of enzalutamide resistance in prostate cancerCancer Drug Resistance · 2019
- Somatic pharmacogenomics of gastrointestinal stromal tumorCancer Drug Resistance · 2019
- Alkylating anticancer agents and their relations to microRNAsCancer Drug Resistance · 2019
- PARP inhibitors: clinical development, emerging differences, and the current therapeutic issuesCancer Drug Resistance · 2019
- MicroRNAs in neuroblastoma tumorigenesis, therapy resistance, and disease evolutionCancer Drug Resistance · 2019
- Resistance to anti-tubulin agents: From vinca alkaloids to epothilonesCancer Drug Resistance · 2019
- Lipid metabolic reprogramming as an emerging mechanism of resistance to kinase inhibitors in breast cancerCancer Drug Resistance · 2019
- Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeuticsCancer Drug Resistance · 2019
- Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogsCancer Drug Resistance · 2019
- Mitochondrial determinants of chemoresistanceCancer Drug Resistance · 2019
- The effects of growth hormone on therapy resistance in cancerCancer Drug Resistance · 2019
- Long non-coding RNAs regulation of therapeutic resistanceCancer Drug Resistance · 2019
- Targeting MYCN and ALK in resistant and relapsing neuroblastomaCancer Drug Resistance · 2019
- The bone marrow microenvironment as a mediator of chemoresistance in acute lymphoblastic leukemiaCancer Drug Resistance · 2019
- Cancer stem cells in neuroblastoma therapy resistanceCancer Drug Resistance · 2019
- Pharmacogenetics implementation in the clinics: information and guidelines for germline variantsCancer Drug Resistance · 2019
- How to conjugate the stemness marker ALDH1A1 with tumor angiogenesis, progression, and drug resistanceCancer Drug Resistance · 2019
- The importance of epithelial-mesenchymal transition and autophagy in cancer drug resistanceCancer Drug Resistance · 2019
- Use of MRI, metabolomic, and genomic biomarkers to identify mechanisms of chemoresistance in gliomaCancer Drug Resistance · 2019
- Pharmacogenetics of thiopurinesCancer Drug Resistance · 2019
- The role of exosomal microRNAs; focus on clinical applications in breast cancerCancer Drug Resistance · 2019
- Pharmacogenetics implementation in the clinics: information and guidelines for germline variantsCancer Drug Resistance · 2019
- Pharmacogenetic and pharmacogenomic discovery strategiesCancer Drug Resistance · 2019
- Liquid biopsies in myeloid malignanciesCancer Drug Resistance · 2019
- MicroRNAs and cancer drug resistance: over two thousand characters in search of a roleCancer Drug Resistance · 2019
- Exosomal lncRNAs: the newest promising liquid biopsyCancer Drug Resistance · 2019
- The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunitiesCancer Drug Resistance · 2019
- Role of circulating tumor cell spheroids in drug resistanceCancer Drug Resistance · 2019
- Insights into breast cancer phenotying through molecular omics approaches and therapy responseCancer Drug Resistance · 2019
- Emerging targets in cancer drug resistanceCancer Drug Resistance · 2019
- Regulation of ABCB1 activity by microRNA-200c and microRNA-203a in breast cancer cells: the quest for microRNAs’ involvement in cancer drug resistanceCancer Drug Resistance · 2019
- Pharmacogenetics of asparaginase in acute lymphoblastic leukemiaCancer Drug Resistance · 2019
- Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumorsCancer Drug Resistance · 2019
- Circulating non-coding RNAs in recurrent and metastatic ovarian cancerCancer Drug Resistance · 2019
- Involvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell linesCancer Drug Resistance · 2019
- Mechanism of resistance to immune checkpoint inhibitorsCancer Drug Resistance · 2019
- Network rewiring, adaptive resistance and combating strategies in breast cancerCancer Drug Resistance · 2019
- Drug-adapted cancer cell lines as preclinical models of acquired resistanceCancer Drug Resistance · 2019
- Germline variants in cancer therapyCancer Drug Resistance · 2019
- Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapyCancer Drug Resistance · 2019
- Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenaseCancer Drug Resistance · 2019
- Relationship between ovarian cancer stem cells, epithelial mesenchymal transition and tumour recurrenceCancer Drug Resistance · 2019
- Targeting the “undruggable” RAS - new strategies - new hope?Cancer Drug Resistance · 2019
- In search of effective therapies to overcome resistance to Temozolomide in brain tumoursCancer Drug Resistance · 2019
- Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncologyCancer Drug Resistance · 2019
- Colorectal cancer stem cells properties and features: evidence of interleukin-8 involvementCancer Drug Resistance · 2019
- Components of the human-specific, p53-mediated “kill switch” tumor suppression mechanism are usurped by human tumors, creating the possibility of therapeutic exploitationCancer Drug Resistance · 2019
- Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adductsCancer Drug Resistance · 2019
- The use of pharmacogenetics to increase the safety of colorectal cancer patients treatedwith fluoropyrimidinesCancer Drug Resistance · 2019